Lantern Pharma (LTRN) to Release Earnings on Thursday

Lantern Pharma (NASDAQ:LTRN) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Lantern Pharma to post earnings of ($0.46) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Lantern Pharma Stock Down 1.7%

LTRN opened at $2.29 on Thursday. The business has a fifty day moving average of $2.93 and a 200 day moving average of $3.49. Lantern Pharma has a 52-week low of $2.24 and a 52-week high of $5.74. The stock has a market cap of $25.60 million, a P/E ratio of -1.31 and a beta of 1.53.

Hedge Funds Weigh In On Lantern Pharma

A number of institutional investors have recently modified their holdings of LTRN. Cetera Investment Advisers bought a new stake in shares of Lantern Pharma during the fourth quarter valued at approximately $37,000. XTX Topco Ltd bought a new position in Lantern Pharma in the second quarter worth approximately $40,000. CIBC Private Wealth Group LLC purchased a new position in Lantern Pharma during the 4th quarter worth $47,000. Two Sigma Investments LP purchased a new position in Lantern Pharma during the 3rd quarter worth $70,000. Finally, Susquehanna International Group LLP bought a new stake in Lantern Pharma during the 3rd quarter valued at $170,000. 28.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Lantern Pharma in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $25.00.

Lantern Pharma Company Profile

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.